Open-label Study to Investigate Systemic Exposure in Adult and Pediatric Atopic Dermatitis Patients Treated 8.5 Days With Pimecrolimus Cream 1% Under Occlusion
NCT00925730
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
20
Enrollment
INDUSTRY
Sponsor class
Conditions
Atopic Dermatitis
Interventions
DRUG:
Pimecrolimus
Sponsor
Novartis